Glucagon News and Research

RSS

Researchers move one step closer to treating diabetes with human probiotic pill

Science may be one step closer to treating diabetes with a human probiotic pill, according to new Cornell University research.

30 Jan 2015

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management.

25 Dec 2014

Two hormones better than one for hypoglycaemia prevention with artificial pancreas

Artificial pancreas systems significantly improve glycaemic control in adolescents and adults with Type 1 diabetes, shows a head-to-head trial of single- and dual-hormone systems versus a conventional insulin pump.

22 Dec 2014

UB study creates new awareness for diabetics who are at risk for dehydration

Some drugs used to treat diabetes mimic the behavior of a hormone that a University at Buffalo psychologist has learned controls fluid intake in subjects. The finding creates new awareness for diabetics who, by the nature of their disease, are already at risk for dehydration.

12 Dec 2014

Triple hormone reduces body weight, improves insulin sensitivity

Recently, the researchers had constructed several single molecules with dual hormone action. Now, for the first time, the researchers succeeded in designing a substance that combines three metabolically active hormone components (GLP-1, GIP and glucagon) and offers unmatched potency to fight metabolic diseases in pre-clinical trials.

9 Dec 2014

External artificial pancreas improves glucose control, reduces hypoglycemia risk

The world's first clinical trial comparing three alternative treatments for type 1 diabetes was conducted in Montréal by researchers at the IRCM and the University of Montreal, led by endocrinologist Dr. Rémi Rabasa-Lhoret.

27 Nov 2014

CHMP approves Victoza for use in adults with type 2 diabetes, moderate renal impairment

The Committee for Medicinal Products for Human Use today issued a positive opinion for the use of Victoza (liraglutide) in adults with type 2 diabetes and moderate renal impairment.

25 Nov 2014

AADE offers self-care tips for people with diabetes

From Thanksgiving through New Year's Day, the holidays can be fun and heartwarming. They can also be exhausting and stressful.

14 Nov 2014

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

GEP-NETs stands for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). This is a type of rare cancer that is increasing in incidence and prevalence – more on this later.

22 Oct 2014

First three recipients of inaugural Harry Winston Fellowships named

Harry Winston, Inc. and the UCLA Children's Discovery and Innovation Institute have named the first three recipients of the inaugural Harry Winston Fellowships.

7 Oct 2014

Gut hormone-drug combination therapy more effective at improving type 2 diabetes

Combined treatment with a drug that mimics the action of a gut hormone and basal insulin is more effective at improving blood sugar control than other anti-diabetic treatments, with similar rates of hypoglycaemia (dangerously low blood sugar levels) and greater weight loss, a systematic review and meta-analysis published in The Lancet shows.

15 Sep 2014

UT Southwestern researchers discover crucial link between high insulin levels and obesity pathways

UT Southwestern Medical Center researchers have identified a crucial link between high levels of insulin and pathways that lead to obesity, a finding that may have important implications when treating diabetes.

26 Aug 2014

Whey protein drink can control erratic glucose levels associated with type 2 diabetes

Blood sugar surges - after-meal glucose "spikes" - can be life threatening for the 29 million Americans with diabetes. Diabetic blood sugar spikes have been linked to cardiovascular disease, cancer, Alzheimer's disease, kidney failure, and retinal damage.

5 Aug 2014

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S.

29 Jul 2014

Bionic pancreas device controls blood sugar in patients with type 1 diabetes

The latest version of a bionic pancreas device has been successfully tested in two five-day clinical trials - one in adults, the other in adolescents - that imposed minimal restrictions on patient activities.

16 Jun 2014

American Association of Diabetes Educators suggests tips for safe travel

AAA estimates 36.1 million people will travel this Memorial Day weekend. If diabetes is your constant companion, that doesn't mean you can't enjoy traveling, whether traversing America in an RV or flying to the far reaches of the globe. Ensuring you stay healthy and keep your glucose levels on an even keel does require a little bit of organization and planning ahead, though.

23 May 2014

Study reveals surprising relationships between diet and release of hormones that suppress eating

By comparing how gut microbes from human vegetarians and grass-grazing baboons digest different diets, researchers have shown that ancestral human diets, so called "paleo" diets, did not necessarily result in better appetite suppression.

20 May 2014

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Isis Pharmaceuticals, Inc. announced today positive data from a Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy.

14 May 2014

Patients with Parkinson's disease show improvements after exenatide therapy

Follow-Up Study Published in the Journal of Parkinson's Disease Supports an Earlier "Proof of Concept" Trial. A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier "proof of concept" clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy.

9 May 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates.

7 May 2014